SCHEMBL4475367

SCHEMBL4475367

Cc1[nH]c(C)c(-c2c[nH]c(-c3ccc(F)cc3)cc2=O)c(=O)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
KDM4E B2RXH2 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CTSV O60911 1/20 0.37
CTSL P07711 1/20 0.37
ERCC1 P07992 1/20 0.35
ERCC4 Q92889 1/20 0.35
MAPT P10636 1/20 0.34
TYMP P19971 1/20 0.34
PTGS2 P35354 2/20 0.34
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP1B1 Q16678 1/20 0.33
GSK3B P49841 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478743 0.90 SLC2A1 (0.42) MEN1KMT2AKDM4ESMN1; SMN2MAPT
SCHEMBL4483594 0.87 MEN1 (0.31) MEN1KMT2ANPC1RAB9ASLC2A1
SCHEMBL3392240 0.85 PRKAB2 (0.36) MEN1KMT2ACTSVCTSLALDH1A1
SCHEMBL4481795 0.85 ALDH1A1 (0.43) MEN1KMT2AKDM4ESMN1; SMN2MAPT
SCHEMBL4464654 0.85 ADORA2A (0.39) ADORA2AADORA1MEN1KMT2AKDM4E
SCHEMBL4490716 0.84 SCN10A (0.37) PTGS2SLC2A1
SCHEMBL4482112 0.83 L3MBTL1 (0.39) MEN1KMT2AKDM4ESMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL4489667 0.83 SCN10A (0.36) KDM4EPTGS2SLC2A1
SCHEMBL4490983 0.83 ADORA2A (0.41) ADORA2AADORA1KMT2ASMN1; SMN2MAPT
SCHEMBL4490544 0.83 BRD4 (0.39) MEN1KMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP ADORA2A 868/4885ADORA1 319/4885MEN1 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.